Analyst Ratings For PTC Therapeutics, Inc. (NASDAQ:PTCT)
Today, Bank of America raised its price target on PTC Therapeutics, Inc. (NASDAQ:PTCT) to $31.00 per share.
There are 4 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on PTC Therapeutics, Inc. (NASDAQ:PTCT) is Hold with a consensus target price of $28.4286 per share, a potential 24.69% downside.
Some recent analyst ratings include
- 7/24/2018-Citigroup Reiterated Rating of Buy .
- 7/19/2018-Credit Suisse Group initiated coverage with a Outperform rating.
- 6/20/2018-Barclays Upgrade from a “Underweight ” rating to a ” Equal Weight” rating.
- 6/18/2018-William Blair Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
- 6/18/2018-Royal Bank of Canada Upgrade from a “Sector Perform ” rating to a ” Outperform” rating.
Recent Insider Trading Activity For PTC Therapeutics, Inc. (NASDAQ:PTCT)
PTC Therapeutics, Inc. (NASDAQ:PTCT) has insider ownership of 7.50% and institutional ownership of 91.79%.
- On 6/19/2018 Neil Gregory Almstead, EVP, sold 20,000 with an average share price of $48.31 per share and the total transaction amounting to $966,200.00.
- On 6/1/2018 Marcio Souza, COO, sold 5,161 with an average share price of $34.65 per share and the total transaction amounting to $178,828.65.
- On 1/5/2018 Stuart Walter Peltz, CEO, sold 2,230 with an average share price of $18.03 per share and the total transaction amounting to $40,206.90.
- On 1/4/2018 Christine Marie Utter, Insider, sold 412 with an average share price of $17.67 per share and the total transaction amounting to $7,280.04.
- On 1/4/2018 Neil Gregory Almstead, EVP, sold 77 with an average share price of $17.67 per share and the total transaction amounting to $1,360.59.
- On 5/23/2017 Dawn Svoronos, Director, bought 25,000 with an average share price of $13.49 per share and the total transaction amounting to $337,250.00.
- On 1/5/2017 Neil Gregory Almstead, EVP, sold 78 with an average share price of $11.82 per share and the total transaction amounting to $921.96.
About PTC Therapeutics, Inc. (NASDAQ:PTCT)
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy. It is developing Translarna, which is in Phase II clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 for the treatment of patients with spinal muscular atrophy, as well as PTC596, an orally bioavailable and potent small molecule that has completed Phase I study, which targets solid tumor cell populations by reducing the activity and amount of BMI1. The company has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and research collaboration with CHDI Foundation, Inc. to discover and develop small-molecule therapeutics for Huntington's disease. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Recent Trading Activity for PTC Therapeutics, Inc. (NASDAQ:PTCT)
Shares of PTC Therapeutics, Inc. closed the previous trading session at 38,33 up +1,48 4,02 % with 36.78 shares trading hands.